The first patient to be given a new drug for herb octopus "first-in-class" brain tumors has been completed.

On July 23, Herb Octopus announced that it had completed its first patient administration in a phase 1 clinical trial for the treatment of terminal malignancies, new drug NBQ72S (also known as QBS10072S).
NBQ72S is a new type of dual-function small molecule drug targeting human L-type amino acid transporter protein 1 (LAT1), which is the world's first new drug (first-in-class) and is intended to develop and treat malignant tumors such as brain tumors. Founded in 2017,
Herbs octopus is a clinical biopharmaceutical company dedicated to the development of new "first-in-class" new drugs with breakthrough therapeutic potential for the treatment of central nervous system tumors and other malignancies that do not meet clinical needs worldwide.
the ceo of the company is Dr. Yan Shixiang, who is also a partner of Herb Capital. according to
press release, herb Octopus focuses on the development of clinical drugs targeting unique solute carrier (Solute carrier, SLC), the target transporter LAT1 is a super family member of the solute transport protein, which is usually highly expressed in the blood-brain barrier and is highly expressed in most invasive malignancies, such as polymorphic glioblastoma (GBM), breast cancer, lung cancer, and melanoma.
NBQ72S is the world's first innovative dual-function small molecule drug developed by Herb Octopus to target LAT1.
the drug is efficiently and actively transported through the blood-brain barrier through LAT1 to the brain and selectively enters the tumor cells of LAT1, while also protecting normal tissue that does not normally express LAT1 from damage.
in tumor cells, NBQ72S kills tumors by interfering with the DNA replication of rapidly dividing tumor cells.
, the first phase of clinical administration of patients is an open-label, multi-center, single-dose and multi-dose climbing and extended queue clinical study designed to evaluate the safety, tolerance and pharmacodynamics of QBS10072S in patients with advanced or metastatic tumors who have previously been treated with LAT1 and have high expression of LAT1, as well as patients with recurrent or refractory IV astoma. The primary purpose of
study was to determine the maximum tolerable dose, pharmacokinetics, and initial antitumor activity of QBS10072S, which will be entered into the disease-specific extended queue of brain metastasis and astrocytoma at the largest tolerable dose or biologically related dose. Dr. Yan Shixiang, CEO and Partner of Herb Capital,
, said that central nervous system tumors, such as tumor brain metastasis and primary glioblastoma, have huge unmet clinical needs in China and around the world and are in urgent need of effective treatment.
NBQ72S has great potential for treating brain tumors.
successful administration of the first patient is an important milestone for Herb Octopus and its partner, Quadriga BioSciences. Dr. Gordon Ringold, chief executive of
Quadriga BioSciences, said the study is expected to greatly benefit patients with brain metastasis and advanced astrocytes, also known as polymorphic glioblastomas.
Professor of Neuro-Oncology at MD Anderson Cancer Research Center and a member of the Journal of The Moon Program Executive Committee, M.D. According to K. Alfred Yung, one of the main challenges in the development of brain tumor drugs is that most drugs are difficult to pass through the blood-brain barrier.
preclinical studies show that NBQ72S can effectively pass through the blood-brain barrier and enrich brain tumors, and has shown positive effects in animal models of serumines metastasis and glioblastoma caused by triple-negative breast cancer, significantly inhibiting tumor growth and thus improving survival.
he is looking forward to advancing the drug in patients with brain metastasis and polymorphosios.
about 400,000 patients worldwide are diagnosed with primary brain tumors (tumors that originate in the brain or central nervous system) each year, and more than 240,000 die from the disease.
polymorphic glioblastoma is the most common and aggressive primary malignancy in the central nervous system, accounting for up to 47.7%, the patient's five-year survival rate is less than 5%.
current standard first-line treatment options for newly diagnosed GBM patients include surgery, radiotherapy and chemotherapy, but treatment options are very limited, and no first-line treatment of GBM has been approved in the last 15 years.
and most GBM patients will relapse, and there is no standard effective treatment after recurrence, there is a huge unmet clinical needs.
References , Sheb Octopus announced the successful completion of the first patient administration of its first new drug for the treatment of brain tumors worldwide . Retrieved Jul 23, 2020, from.